Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-10-16
1999-12-28
Moezie, F. T.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514 12, 514802, 424101, 424372, 435219, 435226, 530380, 530381, 530382, 530383, 530384, 530385, 530386, A61K 3800, A61K 37547, A61K 3801, A61K 3802
Patent
active
060081996
ABSTRACT:
A method of treatment for human patients with an acquired hypercoagulable state or acquired protein C deficiency associated with sepsis, purpura fulminans, meningococcal sepsis, bone marrow and other transplantations, severe burns, pregnancy, major surgery, severe trauma, or ARDS, which comprises administering activated protein C providing a highly selective therapeutic agent with a low potential for causing bleeding complications.
REFERENCES:
patent: 4775624 (1988-10-01), Bang et al.
patent: 4981952 (1991-01-01), Yan
patent: 4992373 (1991-02-01), Bang et al.
patent: 5009889 (1991-04-01), Taylor, Jr. et al.
patent: 5453373 (1995-09-01), Gerlitz et al.
patent: 5478558 (1995-12-01), Eibl et al.
patent: 5516650 (1996-05-01), Foster et al.
Rivard, G.E. et al., J. Pediatr. 126, 646-652, 1995.
Mesters, et al., "Factor VIIa and Antithrombin III Activity During Severe Sepsis and Septic Shock in Neutropenic Patients", Blood 88: 881-886, 1996.
Fourrier, et al., "Septic Shock, Multiple Organ Failure, and Disseminated Intravascular Coagulation", Chest 101:816-823, 1992.
Taylor, et al., "Protein C Prevents the Coagulopathic and Lethal Effects of Escherichia coli Infusion in the Baboon", J. Clin. Invest. 79:918-925, 1987.
Murakami, et al. "Activated Protein C Attenuates Endotoxin-Induced Pulmonary Vascular Injury by Inhibiting Activated Leukocytes in Rats", Blood 87:642-647, 1996.
Okamoto, et al., "Protective Effect of Neutrophil Elastase Inhibitor (EI) and Activated Protein C (APC) on the Organ Failure and Coagulopathy in Cecal Ligation and Puncture (CLP) Sepsis in the Rabbit", Gastroenterology 106:A747, 1994.
"Anti-Inflammatory Therapies to Treat Sepsis and Septic Shock: A Reassessment", Crit, Care Med. 25:1095-1100, 1997.
Natanson, et al., "Selected Treatment Strategies for Septic Shock Based on Proposed Mechanisms of Pathogenesis", Ann. Intern. Med. 120(9):771-783, 1994.
Gibaldi, "Anatomy of an Antibody, and Related Misadventures in Developing an Effective Treatment for Septic Shock", Pharmacotherapy 13(4) :302-308, 1993.
Parrillo, "Pathogenetic Mechanisms of Septic Shock", N. Engl. J. Med. 328(20):1471-1477, 1993.
Levi, et al., "Pathogenesis of Disseminated Intravascular Coagulation in Sepsis", JAMA 270:975-979, 1993.
Esmon, "The Protein C Anticoagulant Pathway", Arteriosclerosis & Thromb. 12:135-145, 1992.
Taylor, et al., "DEGR-Factor Xa Blocks Disseminated Intravascular Coagulation Initiated by Escherichia coli Without Preventing Shock or Organ Damage", Blood 78:364-368, 1991.
Maraganore, "Hirudin and Hirulog.TM.: Advances in Antithrombotic Therapy", Perspective in Drug Discovery and Design 1:461-478, 1994.
Gerson, et al., "Severe Acquired Protein C Deficiency in Purpura Fulminans Associated with Disseminated Intravascular Coagulation: Treatment with Protein C Concentrate", Pediatrics 91(2):418-422, 1993.
Smith, et al., "Successful Treatment of Meningoccai Induced Protein C Deficiency/Purpura Fulminans in Children with Protein C Concentrate and Heparin", Thromb. Haemost, PS1709, p. 419, 1997.
Rintala, et al., "Protein C in the Treatment of Coagulopathy in Meningococcal Disease", Lancet 347:1767, 1996.
Rivard, et al., "Treatment of Purpura Fulminans in Meningococcemia with Protein C Concentrate", J. Pediatr. 126:646-652, 1995.
Smith, et al., "Use of Protein-C Concentrate, Heparin, and Haemodiafiltration in Meningococcus-Induced Purpura Fulminans", The Lancet 350:1590-1593, 1997.
Veldman, et al., "Treatment of DIC in Septic Shock with Protein C Concentrate", Blood 90:3271, 1997.
Powars, et al., "Epidemic Meningococcemia and Purpura Fulminans with Induced Protein C Deficiency", Clin. Infectious Diseases 17:254-261, 1993.
Haire, et al., "Multiple Organ Dysfunction Syndrome in Bone Marrow Transplantation", JAMA 274:1289-1295, 1995.
Harper, et al., "Protein C Deficiency and Portal Thrombosis in Liver Transplantation in Children", Lancet 924-927, 1988.
Sorenson, et al., "Protein C in Renal Allotransplantation During the Perioperative Period", J. Inter. Med. 226:101-105, 1989.
Gordon, et al;, "Thrombotic Complications of BMT: Association with Protein C Deficiency", Bone Marrow Transplan. 11:61-65, 1993.
Bazarbachi, et al., "Changes in Protein C, Factor VII and Endothelial Markers After Autologous Bone Marrow Transplantation: Possible Implications in the Pathogenesis of Veno-Occlusive Disease", Nouv Rev Fr Hematol 35:135-140, 1993.
Faioni, et al., "Naturally Occurring Anticoagulants and Bone Marrow Transplantation: Plasma Protein C Predicts the Development of Venocclusive Disease of the Liver", Blood 81:3458-3462, 1993.
Collins, et al., "Factor VIIa and Other Haemostatic Variables Following Bone Marrow Transplantation", Throm. And Haemo. 72:28-32, 1994.
Harper, et al., "Changes in the Natural Anticoagulants Following Bone Marrow Transplantation", Bone Marrow Trans. 5:39-42, 1990.
Veldman, et al., "A New Option in the Treatment of VOD After BMT: Continuous Infusion of Recombinant Tissue Plasminogen Activator and Protein C", Bone Marrow Trans. 21:S238, 1998.
Curreri, et al., "Coagulation Dynamics Following Thermal Injury", Ann. Surg. 181:161-163, 1974.
McManus, et al., "Disseminated Intravascular Coagulation in Burned Patients", J. Of Trauma 13(5):416-422, 1973.
Lo, et al., "Protein C and Protein S Levels in Some Burn Patients", Burns 20:186-187, 1994.
Barbour, et al., "Controversies in Thromboembolic Disease During Pregnancy: A Critical Review", Obstet. Gynecol. 86(4):621-633, 1995.
Dahlback, et al., "Inherited Thrombophilia: Resistance to Activated Protein C as a Pathogenic Factor of Venous Thromboembolism", Blood 85:607-614, 1995.
Conrad, et al., "Thrombosis and Pregnancy in Cogenital Deficiencies in AT III, Protein C or Protein S: Study of 78 Women", Throm. Haemost. 63:319-320, 1990.
Perry, et al., "Abnormal Hemostasis and Coagulopathy in Preeclampsia and Eclampsia", Clin. Obstet. Gynecol. 35:338-350, 1992.
Uzan, et al., "Elements de Physiopathologie de la Pre-Eclampsie et Place des Principaux Examens Complementaries", Rev Fr Gynecol. Obstet. 86:158-163, 1991.
Rathgeber, et al., Anasthesiologische und Intensivmedizinische Aspekte der Schweren Praeklampsie Mit HELLP-Syndrom, Anasth Intensivther Notfallmed 25:206-211, 1990.
De Stefano, et al., "Thrombotic Risk during Pregnancy and Puerperium in Women with APC-Resistance--Effective Subcutaneous Heparin Prophylaxis in a Pregnant Patient", Thromb Haemost 74:793-794, 1995.
Watkins, et al.a, "The Early Diagnosis of Impending Coagulopathies Following Surgery and Multiple Trauma", Klin Worchenschr 63:1019-1027, 1985.
Thomas, et al., "Primary Hypercoagulable States in General and Vascular Surgery", Am. J. Surgery 158:491-494, 1989.
LeClerc, J. R., "Low-Molecular Weight Heparin Prophylaxis in Surgical Patients", Clin. Appl. Thrombosis/Hemostasis 3(3):153-156, 1997.
Collins, et al., "Pitfalls in Peripheral Vascular Surgery: Disseminated Intravascular Coagulation", Am. J. Surgery 124:375-380, 1977.
Menges, et al., "The Role of the Protein C-Thrombomodulin System and Fibrinolysis During Cardiovascular Surgery: Influence of Acute Preoperative Plasmapheresis", J. Cardiothor Vasc An. 10:482-489, 1996.
Mayer, et al., "Coagulopathies Associated With Major Spinal Surgery", Clin. Orthop. 245:83-89, 1989.
Blamey, et al, "Protein C Antigen Levels in Major Abdominal Surgery: Relationships to Deep Vein Thrombosis, Malignancy and Treatment with Stanozolol", Thromb. Haemost. 54:622-625, 1985.
Grinnell, et al., "Trans-Activated Expression of Fully Gamma-Carboxylated Recombinant Human Protein C, An Antithrombotic Factor", Bio/Technology 5:1189-1192, 1987.
Graybill, et al., "Complement and Coagulation in Rocky Mountain Spotted Fever", Southern Medical Journal, 66(4):414-413, 1973.
Loubser, et al., "Severe Illness caused by Rickettsia conorii", Annals of Tropical Paediatrics 13:277-280, 1993.
Koul, et al., "Haemostatic Abnormalities in Multidrug-Resistant Enteric Fever", Acta Haematol 93:13-19, 1995.
Carpenter, et al., "Purpura Fulminans in Pneumococcal Sepsis: Case Report and Review", Scand J Infect Dis 29:479-483, 1997.
Butler, et al., "Yersinia pestis Infection in Vi
Grinnell Brian William
Hartman Daniel Lawrence
Yan Sau-Chi Betty
Barrett Brian P.
Eli Lilly and Company
Moezie F. T.
LandOfFree
Methods for treating hypercoagulable states or acquired protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating hypercoagulable states or acquired protein , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating hypercoagulable states or acquired protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2382487